This is an open-label study to determine the pharmacokinetics of a new tablet formulation of
GLPG1972 and to compare it with this of the liquid solution used during the First-in-Human
study (GLPG1972-CL-101). The impact of food intake on the oral bioavailability of GLPG1972
administered as tablet will also be investigated in this study. A dose of 600 mg has been
selected. The study is a phase I randomized open-label cross-over study with three single
dose treatments:
A) 600 mg GLPG1972 oral solution after overnight fast,
B) 600 mg GLPG1972 oral tablet after overnight fast,
C) 600 mg GLPG1972 oral tablet 30 minutes after high-fat high-calorie breakfast.
A washout of at least 6 days between subsequent dosing days is respected so that no
measurable plasma levels or biologically significant effects are remaining. There will be
frequent assessment of adverse experiences post-dose. Twelve healthy male subjects will be
selected according to the inclusion and exclusion criteria and 2 subjects each will be
randomized to one of the 6 treatment sequences (ABC, ACB, BAC, BCA, CAB, CBA)